United Therapeutics Co. (NASDAQ:UTHR) EVP Sells $3,367,980.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $11,261,606.58. This represents a 23.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Performance

UTHR traded up $0.68 during midday trading on Monday, reaching $293.14. 68,546 shares of the company were exchanged, compared to its average volume of 449,113. United Therapeutics Co. has a one year low of $230.39 and a one year high of $417.82. The company’s fifty day moving average price is $333.78 and its 200 day moving average price is $354.54. The company has a market cap of $13.17 billion, a price-to-earnings ratio of 12.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same quarter in the prior year, the business posted $4.36 EPS. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Hedge funds have recently made changes to their positions in the company. Milestone Asset Management LLC grew its stake in United Therapeutics by 56.5% in the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 1,037 shares in the last quarter. Korea Investment CORP grew its position in shares of United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company’s stock valued at $13,863,000 after purchasing an additional 2,300 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock valued at $3,326,000 after purchasing an additional 789 shares during the period. JPMorgan Chase & Co. boosted its stake in United Therapeutics by 35.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after purchasing an additional 50,291 shares during the period. Finally, Burney Co. grew its holdings in United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after buying an additional 12,705 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on UTHR. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.